PODD earnings analysis
What we found in PODD's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Insulet Corporation's Q1 2026 results showcased strong growth, with revenue of $761.7 million and an EPS of $1.42, exceeding estimates and reflecting a 33.9% increase from the prior year. The growth was driven primarily by robust sales of Omnipod products in both the U.S. (up 28.3%) and international markets (up 59.4%). The company continues to expand its Omnipod 5 product in new markets while navigating increased costs and a decline in gross margin.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Significant Revenue Growth
- Revenue grew by 33.9% year-over-year to $761.7 million from $569.0 million.
- Strong EPS Beat
- Reported EPS of $1.42 surpassed estimates of $1.18.
- U.S. Omnipod Sales Surge
- U.S. revenue from Omnipod products rose by 28.3% to $515.6 million.
- International Sales High
- International revenue increased by 59.4% to $242.9 million.
- Improved Free Cash Flow
- Free cash flow increased to $89.5 million from $51.6 million year-over-year.
- Raising Full-Year Guidance
- Management anticipates 21%-23% growth in total revenue for the full year.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Declining Gross Margin
- Gross margin decreased from 71.9% to 69.5%, impacted by inventory reserves and warranty costs.
- Increased Debt Levels
- Debt-to-total capital ratio increased to 42% from 39%.
- Regulatory Costs
- Estimated costs related to a voluntary medical device correction are around $30 million, affecting margins.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $1.42
- Gross margin
- 69.5%
- Segment
- U.S. Omnipod: $515.6M; International Omnipod: $242.9M; Drug Delivery: $3.3M
What they said about what is next.
Management raised full-year revenue guidance to reflect stronger demand and growth expectations.
The filing reads better than the one before it.
What came before.
- 10-K · February 18, 2026
- Insulet reported strong 2025 operating performance with total revenue up 30.7% to $2,708.1 million driven by Omnipod product volume and international rollouts; gross margin expanded to 71.6% and free cash flow rose to…
- 10-Q · May 9, 2025
- Insulet reported Q1 revenue of $569.0M, up $127.3M (+28.8%) year-over-year, with gross profit of $409.0M (71.9% gross margin) and operating income of $88.8M (15.6% operating margin). GAAP diluted EPS was $0.50 and net…
- 10-Q · November 8, 2024
- Insulet reported a strong Q3: total revenue of $543.9M (up $111.2M or 25.7% vs Q3 2023) and diluted EPS of $1.08 (vs $0.74). Gross profit was $377.1M (gross margin ~69.3%) and operating income was $88.1M (operating…
- 10-Q · August 9, 2024
- Insulet reported a strong quarter of operational growth: Q2 revenue was $488.5 million (up $92.0 million vs. Q2 2023) with improved operating margin of 11.2% and gross profit of $330.9 million. Net income of $188.6…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing PODD makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever